Evidence map›Paper›PMID 29370570›Full record

ArticleCancer biology & therapy2018

PIK3R3 promotes chemotherapeutic sensitivity of colorectal cancer through PIK3R3/NF-kB/TP pathway.

Sidikjan Ibrahim, Guodong Li, Fuqing Hu, Zhenlin Hou, Qianzhi Chen, Geng Li, Xuelai Luo, Junbo Hu, Yongdong Feng

Open access · bronzeAbstract read
In one paragraph

Article in Cancer biology & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. OncogenicMedComm · 2024
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Pharmacogenomics of 5-fluorouracil in colorectal cancer: review and update.Cellular oncology (Dordrecht, Netherlands) · 2020
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Sidikjan Ibrahima Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology , Wuhan , China.
Guodong Lia Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology , Wuhan , China.
Fuqing Hua Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology , Wuhan , China.
Zhenlin Houa Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology , Wuhan , China.
Qianzhi Chena Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology , Wuhan , China.
Geng Lia Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology , Wuhan , China.
Xuelai Luoa Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology , Wuhan , China.
Junbo Hua Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology , Wuhan , China.
Yongdong Fenga Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology , Wuhan , China.
Tongji Hospital · CNHuazhong University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phosphoinositide-3-kinase regulatory subunit 3(PIK3R3) is overexpressed in different types of human cancer. We previously reported the important role of PIK3R3 in colorectal cancer (CRC). However, the prognosis effect of PIK3R3 in CRC is still remaining unclear. In this study, we explored online clinical databases to analyze the prognosis differences between higher and lower expression of PIK3R3 in CRC patients. Interestingly, we found that better disease-free survival (DFS) were occurred in patients with higher expression of PIK3R3, but there is no significant difference in overall survival (OS). For further, we showed that PIK3R3 could enhance 5-FU induced apoptosis by regulating the expression of thymmidine phosphorylase (TP). In conclusion, PIK3R3 could be considered as a predictor of 5-FU sensitivity for personalized treatment, and a therapeutic target for colorectal cancer.

Indexed as

AnimalsAntimetabolites, AntineoplasticApoptosisColorectal NeoplasmsDatasets as TopicDisease-Free SurvivalDrug Resistance, NeoplasmFemaleFluorouracilHT29 CellsHumansKaplan-Meier EstimateMiceMice, NudeNF-kappa BPhosphatidylinositol 3-KinasesAntimetabolites, AntineoplasticFluorouracilNF-kappa BPhosphatidylinositol 3-KinasesPIK3R3 protein, humanThymidine Phosphorylase5-fluorouracilColon cancerDisease free survivaloverall survivalPhosphoinositide-3-kinase regulatory subunit 3 (PIK3R3)

Identifiers

PMID29370570
PMCPMC5790378
OpenAlexW2790207627

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.